Cytomegalovirus infection complicating immunosuppressive therapy for dermatomyositis

Acta Dermato-Venereologica

Volumn 86, Issue 6, 2006, Pages 535-537

  Hashimoto, Akira ^a   Okuyama, Ryuhei ^a   Watanabe, Hiroshi ^a   Tagami, Hachiro ^a   Aiba, Setsuya ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Cytomegalovirus; Dermatomyositis; Opportunistic infection

Indexed keywords

CYCLOPHOSPHAMIDE; GANCICLOVIR; IMMUNOGLOBULIN; PREDNISOLONE;

AGED; ARTICLE; CASE REPORT; CLINICAL FEATURE; CYTOMEGALOVIRUS INFECTION; DERMATOMYOSITIS; DISEASE COURSE; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG DOSE REGIMEN; DRUG WITHDRAWAL; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LABORATORY TEST; MORTALITY; OPPORTUNISTIC INFECTION; PATIENT MONITORING; PHYSICAL EXAMINATION; PRIORITY JOURNAL; RADIODIAGNOSIS;

AGED; ANTIVIRAL AGENTS; CYCLOPHOSPHAMIDE; CYTOMEGALOVIRUS INFECTIONS; DERMATOMYOSITIS; FATAL OUTCOME; FEMALE; GANCICLOVIR; GLUCOCORTICOIDS; HUMANS; IMMUNOCOMPETENCE; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOSUPPRESSIVE AGENTS; OPPORTUNISTIC INFECTIONS; PREDNISOLONE;

EID: 33845643709     PISSN: 00015555     EISSN: None     Source Type: Journal    
DOI: 10.2340/00015555-0152     Document Type: Article

References (8)

1. Viguier M, Fouere S, de la Salmoniere P, Rabian C, Lebbe C, Dubertret L, et al. Peripheral blood lymphocyte subset counts in patients with dermatomyositis: clinical correlations and changes following therapy. Medicine (Baltimore) 2003; 82: 82-86.
2. Marie I, Hachulla E, Cherin P, Hellot MF, Herson S, Levesque H, Hatron PY. Opportunistic infections in polymyositis and dermatomyositis. Arthritis Rheum 2005; 53: 155-165.
3. Sepkowitz KA. Opportunistic infections in patients with and patients without Acquired Immunodeficiency Syndrome. Clin Infect Dis 2002; 34: 1098-1107.
4. Kasifoglu T, Korkmaz C, Ozkan R. Cytomegalovirus-induced interstitial pneumonitis in a patient with dermatomyositis. Clin Rheumatol 2006; 25: 731-733.
5. Nichols WG, Boeckh M. Recent advances in the therapy and prevention of CMV infections. J Clin Virol 2000; 16: 25-40.
6. Humar A, O'Rourke K, Lipton J, Messner H, Meharchand J, Mahony J, et al. The clinical utility of CMV surveillance cultures and antigenemia following bone marrow transplantation. Bone Marrow Transplant 1999; 23: 45-51.
7. Razonable RR, Paya CV, Smith TF. Role of the laboratory in diagnosis and management of cytomegalovirus infection in hematopoietic stem cell and solid-organ transplant recipients. J Clin Microbiol 2002; 40: 746-752.
8. Hodson EM, Jones CA, Webster AC, Strippoli GF, Barclay PG, Kable K, et al. Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solid-organ transplants: a systematic review of randomised controlled trials. Lancet 2005; 365: 2105-2115.